DrugPatentWatch Database Preview
Clovis Oncology Inc Company Profile
What is the competitive landscape for CLOVIS ONCOLOGY INC, and what generic alternatives to CLOVIS ONCOLOGY INC drugs are available?
There are nine US patents protecting CLOVIS ONCOLOGY INC drugs.
There are two hundred and six patent family members on CLOVIS ONCOLOGY INC drugs in fifty-two countries and twelve supplementary protection certificates in eleven countries.
Summary for Clovis Oncology Inc
| International Patents: | 206 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Clovis Oncology Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,071,579 | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,071,579 | ➤ Sign Up | ➤ Sign Up | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 9,045,487 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Clovis Oncology Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,662,818 | Phthalazinone derivatives | ➤ Sign Up |
| 8,912,187 | Phthalazinone derivatives | ➤ Sign Up |
| 6,977,298 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | ➤ Sign Up |
| 7,449,464 | Phthalazinone derivatives | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Clovis Oncology Inc Drugs
Supplementary Protection Certificates for Clovis Oncology Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015016,C1633724 | Lithuania | ➤ Sign Up | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| 3 50005-2015 | Slovakia | ➤ Sign Up | PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218 |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| 15/016 | Ireland | ➤ Sign Up | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
